[10-Q] Enanta Pharmaceuticals, Inc Quarterly Earnings Report
Enanta Pharmaceuticals reported stable royalty-driven revenue but continued operating losses while advancing multiple clinical and preclinical programs. Royalty revenue was $18.3 million for the quarter and $50.2 million for the nine months ended June 30, 2025. The company posted a net loss of $18.3 million for the quarter and $63.2 million for the nine months, and had an accumulated deficit of $386.2 million as of June 30, 2025.
Enanta held $204.1 million in cash, cash equivalents and short-term marketable securities and stated that these resources, together with retained royalty cash flows, are expected to fund operations into fiscal 2028. The company recorded a $147.7 million liability related to a $200.0 million royalty sale transaction and continues to recognize 100% of HCV royalties as revenue. Clinical updates include positive pediatric topline results for zelicapavir, completion of enrollment in a Phase 2b high-risk adult zelicapavir study (topline expected September 2025), positive Phase 2a challenge results for EDP-323, Phase 2 results for EDP-235, and progression of immunology programs (KIT and STAT6). The company has appealed a district court decision invalidating a patent asserted against Pfizer; appeal briefs have been filed.
Enanta Pharmaceuticals ha riportato ricavi da royalty stabili ma ha continuato a registrare perdite operative mentre avanza su più programmi clinici e preclinici. I ricavi da royalty sono stati 18,3 milioni di dollari nel trimestre e 50,2 milioni nei nove mesi terminati il 30 giugno 2025. L'azienda ha chiuso il trimestre con una perdita netta di 18,3 milioni e i nove mesi con una perdita netta di 63,2 milioni; il deficit accumulato ammontava a 386,2 milioni al 30 giugno 2025.
Enanta disponeva di 204,1 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili a breve termine e ha dichiarato che queste risorse, insieme ai flussi di cassa derivanti dalle royalty trattenute, dovrebbero finanziare le operazioni fino all'esercizio 2028. La società ha registrato una passività di 147,7 milioni relativa a una cessione di royalty da 200,0 milioni e continua a contabilizzare il 100% delle royalty HCV come ricavo. Aggiornamenti clinici includono risultati positivi topline pediatrici per zelicapavir, completamento arruolamento nello studio Phase 2b su adulti ad alto rischio per zelicapavir (risultati topline attesi a settembre 2025), risultati positivi della Phase 2a challenge per EDP-323, risultati di Phase 2 per EDP-235 e progressi nei programmi di immunologia (KIT e STAT6). La società ha impugnato una decisione di tribunale distrettuale che aveva invalidato un brevetto fatto valere contro Pfizer; sono stati depositati i memoriali d'appello.
Enanta Pharmaceuticals informó ingresos por royalties estables, pero siguió registrando pérdidas operativas mientras avanza múltiples programas clínicos y preclínicos. Los ingresos por royalties fueron de 18,3 millones de dólares en el trimestre y 50,2 millones en los nueve meses terminados el 30 de junio de 2025. La compañía registró una pérdida neta de 18,3 millones en el trimestre y de 63,2 millones en los nueve meses; el déficit acumulado era de 386,2 millones al 30 de junio de 2025.
Enanta tenía 204,1 millones de dólares en efectivo, equivalentes de efectivo y valores negociables a corto plazo y declaró que estos recursos, junto con los flujos de efectivo por royalties retenidas, deberían financiar las operaciones hasta el ejercicio 2028. La compañía registró un pasivo de 147,7 millones relacionado con una transacción de venta de royalties por 200,0 millones y sigue reconociendo el 100% de las royalties HCV como ingresos. Las actualizaciones clínicas incluyen resultados topline pediátricos positivos para zelicapavir, finalización del reclutamiento en el estudio Phase 2b en adultos de alto riesgo para zelicapavir (topline esperado en septiembre de 2025), resultados positivos de Phase 2a challenge para EDP-323, resultados de Phase 2 para EDP-235 y avance de los programas de inmunología (KIT y STAT6). La compañía apeló una decisión del tribunal de distrito que invalidó una patente ejercida contra Pfizer; se han presentado los escritos de apelación.
엔언타 파마슈티컬스는 로열티 기반 수익이 안정적이었지만 여러 임상 및 전임상 프로그램을 진행하는 가운데 영업손실을 계속 기록했습니다. 로열티 수익은 해당 분기 동안 1,830만 달러, 2025년 6월 30일 종료된 9개월 누적 기준으로 5,020만 달러였습니다. 회사는 분기 순손실 1,830만 달러, 9개월 순손실 6,320만 달러를 기록했으며, 2025년 6월 30일 기준 누적 적자는 3억 8,620만 달러였습니다.
엔언타는 현금·현금성자산 및 단기 유동증권으로 2억 4.1백만 달러를 보유하고 있으며, 이러한 자원과 보유 로열티로 인한 현금흐름이 2028 회계연도까지 운영 자금을 지원할 것으로 보고했습니다. 회사는 2억 달러 로열티 매각 거래와 관련해 1억 4,770만 달러의 부채를 계상했으며, HCV 로열티 전액(100%)을 수익으로 인식하기로 계속했습니다. 임상 업데이트로는 zelicapavir 소아 톱라인 긍정 결과, 고위험 성인 대상 Phase 2b zelicapavir 연구의 등록 완료(톱라인 결과 2025년 9월 예정), EDP-323의 Phase 2a 챌린지 긍정 결과, EDP-235의 Phase 2 결과 및 면역학 프로그램(KIT 및 STAT6)의 진전이 포함됩니다. 회사는 화이자에 대해 주장된 특허를 무효로 한 지방법원 판결에 대해 항소했으며, 항소 서면이 제출되었습니다.
Enanta Pharmaceuticals a déclaré des revenus stables tirés des redevances, mais continue d'afficher des pertes d'exploitation tout en progressant sur plusieurs programmes cliniques et précliniques. Les revenus de redevances se sont élevés à 18,3 millions de dollars pour le trimestre et à 50,2 millions pour les neuf mois clos le 30 juin 2025. La société a enregistré une perte nette de 18,3 millions pour le trimestre et de 63,2 millions pour les neuf mois ; le déficit accumulé s'élevait à 386,2 millions au 30 juin 2025.
Enanta disposait de 204,1 millions de dollars en liquidités, équivalents de trésorerie et titres négociables à court terme et indique que ces ressources, ainsi que les flux de trésorerie issus des redevances retenues, devraient financer les opérations jusqu'à l'exercice 2028. La société a comptabilisé une dette de 147,7 millions liée à une opération de vente de redevances de 200,0 millions et continue de comptabiliser 100 % des redevances HCV en tant que revenus. Les actualités cliniques incluent des résultats topline pédiatriques positifs pour le zelicapavir, la fin du recrutement de l'étude Phase 2b chez des adultes à haut risque pour zelicapavir (résultats topline attendus en septembre 2025), des résultats positifs de Phase 2a challenge pour EDP-323, des résultats de Phase 2 pour EDP-235 et la progression des programmes en immunologie (KIT et STAT6). La société a fait appel d'une décision d'un tribunal de district annulant un brevet mis en cause contre Pfizer ; les mémoires d'appel ont été déposés.
Enanta Pharmaceuticals meldete stabile royalty-basierte Einnahmen, verzeichnete jedoch weiterhin operative Verluste, während mehrere klinische und präklinische Programme vorangetrieben wurden. Die Royalty-Einnahmen beliefen sich im Quartal auf 18,3 Mio. USD und in den neun Monaten zum 30. Juni 2025 auf 50,2 Mio. USD. Das Unternehmen wies im Quartal einen Nettoverlust von 18,3 Mio. USD und in den neun Monaten einen Nettoverlust von 63,2 Mio. USD aus; der kumulierte Fehlbetrag belief sich zum 30. Juni 2025 auf 386,2 Mio. USD.
Enanta hielt 204,1 Mio. USD in Zahlungsmitteln, Zahlungsmitteläquivalenten und kurzfristig handelbaren Wertpapieren und erklärte, dass diese Mittel zusammen mit den einbehaltenen Royalty-Cashflows voraussichtlich bis ins Geschäftsjahr 2028 hinein die Geschäftstätigkeit finanzieren werden. Das Unternehmen verbuchte eine Verbindlichkeit von 147,7 Mio. USD im Zusammenhang mit einer 200,0-Mio.-USD-Royalty-Verkaufstransaktion und erkennt weiterhin 100 % der HCV-Royalties als Umsatz an. Klinische Updates umfassen positive pädiatrische Topline-Ergebnisse für Zelicapavir, den abgeschlossenen Einschluss in die Phase-2b-Studie bei hochriskanten Erwachsenen für Zelicapavir (Topline-Ergebnisse erwartet September 2025), positive Phase-2a-Challenge-Ergebnisse für EDP-323, Phase-2-Ergebnisse für EDP-235 sowie Fortschritte in den Immunologieprogrammen (KIT und STAT6). Das Unternehmen hat gegen eine Entscheidung des Bezirksgerichts, die ein gegen Pfizer geltend gemachtes Patent für ungültig erklärte, Berufung eingelegt; Berufungsunterlagen wurden eingereicht.
- $204.1 million in cash, cash equivalents and short-term marketable securities, with management stating runway into fiscal 2028
- Royalty revenue stability: $18.3 million in the quarter and $50.2 million year-to-date driven by MAVYRET/MAVIRET royalties
- Clinical progress: Positive pediatric topline results for zelicapavir and highly significant Phase 2a challenge results for EDP-323 (p<0.0001)
- Continued operating losses: net loss of $18.3 million for the quarter and $63.2 million for the nine months ended June 30, 2025
- Liability from royalty sale: $147.7 million balance related to the $200.0 million royalty sale, creating future cash obligations to OMERS
- Patent litigation setback: district court ruled asserted patent invalid; company has appealed and outcome timing is uncertain
Insights
TL;DR: Royalty revenue steady and cash runway into 2028 reduce near-term financing risk, but operating losses persist.
Revenue of $18.3 million in the quarter and $50.2 million year-to-date remains driven by AbbVie royalties for MAVYRET/MAVIRET. Operating losses continue: $18.3 million for the quarter and $63.2 million for nine months, but operating cash outflow improved to $12.8 million for the nine months versus $68.4 million prior-year. Liquidity of $204.1 million provides runway into fiscal 2028 per management, while the $147.7 million royalty sale liability represents a material contractual payment obligation. Reduced R&D and G&A expense year-over-year improved cash trends, but reliance on a single large royalty stream and the structured payout to OMERS are key financial considerations for investors.
TL;DR: Clinical data reinforce the RSV franchise and antiviral pipeline, supporting program value though commercialization remains future-dependent.
Zelicapavir showed favorable safety and antiviral activity in a pediatric Phase 2 study with selected dosing and antiviral effects (up to 1.4 log decline at Day 5 in Part 2 and stronger effect when randomized within 3 days of symptom onset). A Phase 2b high-risk adult study completed enrollment of 186 patients with topline expected September 2025. EDP-323 achieved highly statistically significant reductions in viral load and symptoms in a Phase 2a challenge study (p<0.0001). EDP-235 met the primary endpoint in a Phase 2 COVID-19 study with symptom improvements in the 400 mg group. Immunology programs advanced with EPS-1421 selected as a KIT lead and STAT6 work targeting a H2 2025 lead candidate selection. These clinical and preclinical milestones materially increase program de-risking, though commercialization and partnership execution remain critical next steps.
Enanta Pharmaceuticals ha riportato ricavi da royalty stabili ma ha continuato a registrare perdite operative mentre avanza su più programmi clinici e preclinici. I ricavi da royalty sono stati 18,3 milioni di dollari nel trimestre e 50,2 milioni nei nove mesi terminati il 30 giugno 2025. L'azienda ha chiuso il trimestre con una perdita netta di 18,3 milioni e i nove mesi con una perdita netta di 63,2 milioni; il deficit accumulato ammontava a 386,2 milioni al 30 giugno 2025.
Enanta disponeva di 204,1 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili a breve termine e ha dichiarato che queste risorse, insieme ai flussi di cassa derivanti dalle royalty trattenute, dovrebbero finanziare le operazioni fino all'esercizio 2028. La società ha registrato una passività di 147,7 milioni relativa a una cessione di royalty da 200,0 milioni e continua a contabilizzare il 100% delle royalty HCV come ricavo. Aggiornamenti clinici includono risultati positivi topline pediatrici per zelicapavir, completamento arruolamento nello studio Phase 2b su adulti ad alto rischio per zelicapavir (risultati topline attesi a settembre 2025), risultati positivi della Phase 2a challenge per EDP-323, risultati di Phase 2 per EDP-235 e progressi nei programmi di immunologia (KIT e STAT6). La società ha impugnato una decisione di tribunale distrettuale che aveva invalidato un brevetto fatto valere contro Pfizer; sono stati depositati i memoriali d'appello.
Enanta Pharmaceuticals informó ingresos por royalties estables, pero siguió registrando pérdidas operativas mientras avanza múltiples programas clínicos y preclínicos. Los ingresos por royalties fueron de 18,3 millones de dólares en el trimestre y 50,2 millones en los nueve meses terminados el 30 de junio de 2025. La compañía registró una pérdida neta de 18,3 millones en el trimestre y de 63,2 millones en los nueve meses; el déficit acumulado era de 386,2 millones al 30 de junio de 2025.
Enanta tenía 204,1 millones de dólares en efectivo, equivalentes de efectivo y valores negociables a corto plazo y declaró que estos recursos, junto con los flujos de efectivo por royalties retenidas, deberían financiar las operaciones hasta el ejercicio 2028. La compañía registró un pasivo de 147,7 millones relacionado con una transacción de venta de royalties por 200,0 millones y sigue reconociendo el 100% de las royalties HCV como ingresos. Las actualizaciones clínicas incluyen resultados topline pediátricos positivos para zelicapavir, finalización del reclutamiento en el estudio Phase 2b en adultos de alto riesgo para zelicapavir (topline esperado en septiembre de 2025), resultados positivos de Phase 2a challenge para EDP-323, resultados de Phase 2 para EDP-235 y avance de los programas de inmunología (KIT y STAT6). La compañía apeló una decisión del tribunal de distrito que invalidó una patente ejercida contra Pfizer; se han presentado los escritos de apelación.
엔언타 파마슈티컬스는 로열티 기반 수익이 안정적이었지만 여러 임상 및 전임상 프로그램을 진행하는 가운데 영업손실을 계속 기록했습니다. 로열티 수익은 해당 분기 동안 1,830만 달러, 2025년 6월 30일 종료된 9개월 누적 기준으로 5,020만 달러였습니다. 회사는 분기 순손실 1,830만 달러, 9개월 순손실 6,320만 달러를 기록했으며, 2025년 6월 30일 기준 누적 적자는 3억 8,620만 달러였습니다.
엔언타는 현금·현금성자산 및 단기 유동증권으로 2억 4.1백만 달러를 보유하고 있으며, 이러한 자원과 보유 로열티로 인한 현금흐름이 2028 회계연도까지 운영 자금을 지원할 것으로 보고했습니다. 회사는 2억 달러 로열티 매각 거래와 관련해 1억 4,770만 달러의 부채를 계상했으며, HCV 로열티 전액(100%)을 수익으로 인식하기로 계속했습니다. 임상 업데이트로는 zelicapavir 소아 톱라인 긍정 결과, 고위험 성인 대상 Phase 2b zelicapavir 연구의 등록 완료(톱라인 결과 2025년 9월 예정), EDP-323의 Phase 2a 챌린지 긍정 결과, EDP-235의 Phase 2 결과 및 면역학 프로그램(KIT 및 STAT6)의 진전이 포함됩니다. 회사는 화이자에 대해 주장된 특허를 무효로 한 지방법원 판결에 대해 항소했으며, 항소 서면이 제출되었습니다.
Enanta Pharmaceuticals a déclaré des revenus stables tirés des redevances, mais continue d'afficher des pertes d'exploitation tout en progressant sur plusieurs programmes cliniques et précliniques. Les revenus de redevances se sont élevés à 18,3 millions de dollars pour le trimestre et à 50,2 millions pour les neuf mois clos le 30 juin 2025. La société a enregistré une perte nette de 18,3 millions pour le trimestre et de 63,2 millions pour les neuf mois ; le déficit accumulé s'élevait à 386,2 millions au 30 juin 2025.
Enanta disposait de 204,1 millions de dollars en liquidités, équivalents de trésorerie et titres négociables à court terme et indique que ces ressources, ainsi que les flux de trésorerie issus des redevances retenues, devraient financer les opérations jusqu'à l'exercice 2028. La société a comptabilisé une dette de 147,7 millions liée à une opération de vente de redevances de 200,0 millions et continue de comptabiliser 100 % des redevances HCV en tant que revenus. Les actualités cliniques incluent des résultats topline pédiatriques positifs pour le zelicapavir, la fin du recrutement de l'étude Phase 2b chez des adultes à haut risque pour zelicapavir (résultats topline attendus en septembre 2025), des résultats positifs de Phase 2a challenge pour EDP-323, des résultats de Phase 2 pour EDP-235 et la progression des programmes en immunologie (KIT et STAT6). La société a fait appel d'une décision d'un tribunal de district annulant un brevet mis en cause contre Pfizer ; les mémoires d'appel ont été déposés.
Enanta Pharmaceuticals meldete stabile royalty-basierte Einnahmen, verzeichnete jedoch weiterhin operative Verluste, während mehrere klinische und präklinische Programme vorangetrieben wurden. Die Royalty-Einnahmen beliefen sich im Quartal auf 18,3 Mio. USD und in den neun Monaten zum 30. Juni 2025 auf 50,2 Mio. USD. Das Unternehmen wies im Quartal einen Nettoverlust von 18,3 Mio. USD und in den neun Monaten einen Nettoverlust von 63,2 Mio. USD aus; der kumulierte Fehlbetrag belief sich zum 30. Juni 2025 auf 386,2 Mio. USD.
Enanta hielt 204,1 Mio. USD in Zahlungsmitteln, Zahlungsmitteläquivalenten und kurzfristig handelbaren Wertpapieren und erklärte, dass diese Mittel zusammen mit den einbehaltenen Royalty-Cashflows voraussichtlich bis ins Geschäftsjahr 2028 hinein die Geschäftstätigkeit finanzieren werden. Das Unternehmen verbuchte eine Verbindlichkeit von 147,7 Mio. USD im Zusammenhang mit einer 200,0-Mio.-USD-Royalty-Verkaufstransaktion und erkennt weiterhin 100 % der HCV-Royalties als Umsatz an. Klinische Updates umfassen positive pädiatrische Topline-Ergebnisse für Zelicapavir, den abgeschlossenen Einschluss in die Phase-2b-Studie bei hochriskanten Erwachsenen für Zelicapavir (Topline-Ergebnisse erwartet September 2025), positive Phase-2a-Challenge-Ergebnisse für EDP-323, Phase-2-Ergebnisse für EDP-235 sowie Fortschritte in den Immunologieprogrammen (KIT und STAT6). Das Unternehmen hat gegen eine Entscheidung des Bezirksgerichts, die ein gegen Pfizer geltend gemachtes Patent für ungültig erklärte, Berufung eingelegt; Berufungsunterlagen wurden eingereicht.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number
(Exact name of registrant as specified in its charter)
|
||
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
(Registrants telephone number, including area code:) (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|||
|
☒ |
|
Smaller reporting company |
|
|||||
Emerging growth company |
|
|
|
|
|
||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of August 5, 2025, the registrant had
Table of Contents
|
|
Page |
PART I. |
UNAUDITED FINANCIAL INFORMATION |
|
Item 1. |
Condensed Consolidated Financial Statements |
3 |
|
Condensed Consolidated Balance Sheets |
3 |
|
Condensed Consolidated Statements of Operations |
4 |
|
Condensed Consolidated Statements of Comprehensive Loss |
5 |
|
Condensed Consolidated Statements of Stockholders' Equity |
6 |
|
Condensed Consolidated Statements of Cash Flows |
7 |
|
Notes to Condensed Consolidated Financial Statements (unaudited) |
8 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
16 |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
28 |
Item 4. |
Controls and Procedures |
28 |
PART II. |
OTHER INFORMATION |
|
Item 1. |
Legal Proceedings |
28 |
Item 1A. |
Risk Factors |
28 |
Item 5. |
Other Information |
28 |
Item 6. |
Exhibits |
29 |
Signatures |
30 |
|
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “will” or the negative of these terms or other similar expressions. We caution you that the foregoing list may not encompass all of the forward-looking statements made in this Quarterly Report.
Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and as updated in Item 1A herein.
2
PART I—UNAUDITED FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except per share data)
|
|
June 30, |
|
|
September 30, |
|
||
|
|
2025 |
|
|
2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Short-term marketable securities |
|
|
|
|
|
|
||
Accounts receivable |
|
|
|
|
|
|
||
Prepaid expenses and other current assets |
|
|
|
|
|
|
||
Income tax receivable |
|
|
|
|
|
|
||
Short-term restricted cash |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
|
|
|
|
||
Operating lease, right-of-use assets |
|
|
|
|
|
|
||
Long-term restricted cash |
|
|
|
|
|
|
||
Other long-term assets |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
|
$ |
|
||
Accrued expenses and other current liabilities |
|
|
|
|
|
|
||
Liability related to the sale of future royalties |
|
|
|
|
|
|
||
Operating lease liabilities |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Liability related to the sale of future royalties, net of current portion |
|
|
|
|
|
|
||
Operating lease liabilities, net of current portion |
|
|
|
|
|
|
||
Series 1 nonconvertible preferred stock |
|
|
|
|
|
|
||
Other long-term liabilities |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
|
|
|
|
|
|
|||
Stockholders' equity: |
|
|
|
|
|
|
||
Common stock; $ |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Accumulated other comprehensive (loss) gain |
|
|
( |
) |
|
|
|
|
Accumulated deficit |
|
|
( |
) |
|
|
( |
) |
Total stockholders' equity |
|
|
|
|
|
|
||
Total liabilities and stockholders' equity |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Royalty revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss from operations |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Interest and investment income, net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total other income, net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss before income taxes |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Income tax (expense) benefit |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Net loss per share, basic and diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Weighted average common shares outstanding, basic and |
|
|
|
|
|
|
|
|
|
|
|
|
||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands)
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Other comprehensive (loss) income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net unrealized (loss) gain on marketable securities |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Total other comprehensive (loss) income |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Comprehensive loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Additional |
|
|
Other |
|
|
|
|
|
Total |
|
||||||
|
|
Common Stock |
|
|
Paid-In |
|
|
Comprehensive |
|
|
Accumulated |
|
|
Stockholders' |
|
|||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Income (Loss) |
|
|
Deficit |
|
|
Equity |
|
||||||
Balances, September 30, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
Exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Vesting of restricted stock units, net of withholding |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
||
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, December 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
Vesting of restricted stock units, net of withholding |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
||
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, March 31, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
Vesting of restricted stock units, net of withholding |
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, June 30, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Additional |
|
|
Other |
|
|
|
|
|
Total |
|
||||||
|
|
Common Stock |
|
|
Paid-In |
|
|
Comprehensive |
|
|
Accumulated |
|
|
Stockholders' |
|
|||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Income (Loss) |
|
|
Deficit |
|
|
Equity |
|
||||||
Balances, September 30, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
Vesting of restricted stock units, net of withholding |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
||
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, December 31, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
Exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Vesting of restricted stock units, net of withholding |
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, March 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
Exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balances, June 30, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
Nine Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
|
|
|
|
||
Depreciation and amortization expense |
|
|
|
|
|
|
||
Non-cash interest associated with the sale of future royalties |
|
|
( |
) |
|
|
( |
) |
Non-cash royalty revenue |
|
|
( |
) |
|
|
|
|
Amortization of premiums on marketable securities |
|
|
|
|
|
|
||
Loss on disposal of property and equipment |
|
|
|
|
|
|
||
Change in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
( |
) |
|
|
|
|
Prepaid expenses and other current assets |
|
|
|
|
|
( |
) |
|
Income tax receivable |
|
|
|
|
|
( |
) |
|
Operating lease, right-of-use assets |
|
|
|
|
|
|
||
Other long-term assets |
|
|
|
|
|
|
||
Accounts payable |
|
|
( |
) |
|
|
|
|
Accrued expenses |
|
|
( |
) |
|
|
( |
) |
Operating lease liabilities |
|
|
|
|
|
|
||
Other long-term liabilities |
|
|
|
|
|
( |
) |
|
Net cash used in operating activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchase of marketable securities |
|
|
( |
) |
|
|
( |
) |
Proceeds from maturities and sale of marketable securities |
|
|
|
|
|
|
||
Purchase of property and equipment |
|
|
( |
) |
|
|
( |
) |
Net cash provided by investing activities |
|
|
|
|
|
|
||
Cash flows from financing activities |
|
|
|
|
|
|
||
Payments on royalty sale liability, net of imputed interest |
|
|
( |
) |
|
|
( |
) |
Payments for settlement of share-based awards |
|
|
( |
) |
|
|
( |
) |
Proceeds from the exercise of stock options |
|
|
|
|
|
|
||
Net cash used in financing activities |
|
|
( |
) |
|
|
( |
) |
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
|
|
|
|
( |
) |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
|
|
|
|
||
Cash, cash equivalents and restricted cash at end of period |
|
$ |
|
|
$ |
|
||
Supplemental disclosure of non-cash information: |
|
|
|
|
|
|
||
Purchases of fixed assets included in accounts payable and |
|
$ |
|
|
$ |
|
||
Operating lease liabilities arising from obtaining right-of-use assets |
|
$ |
|
|
$ |
|
||
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
||
Cash paid for interest |
|
$ |
|
|
$ |
|
||
Cash received from tenant improvement allowances |
|
$ |
|
|
$ |
|
||
Cash received from income tax refund |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
ENANTA PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(amounts in thousands, except per share data)
1. Nature of the Business and Basis of Presentation
Enanta Pharmaceuticals, Inc. (collectively with its subsidiary, the “Company”), incorporated in Delaware in
The Company is subject to many of the risks common to companies in the biotechnology industry, including but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance reporting capabilities.
Unaudited Interim Financial Information
The condensed consolidated balance sheet as of September 30, 2024 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements as of June 30, 2025 and for the three and nine months ended June 30, 2025 and 2024 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024.
In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of June 30, 2025 and results of operations for the three and nine months ended June 30, 2025 and 2024 and cash flows for the nine months ended June 30, 2025 and 2024 have been made. The results of operations for the three and nine months ended June 30, 2025 are not necessarily indicative of the results of operations that may be expected for subsequent quarters or the year ending September 30, 2025.
The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts in the condensed consolidated financial statements and in the notes to the condensed consolidated financial statements, except per share amounts, are in thousands unless otherwise indicated.
The accompanying condensed consolidated financial statements have been prepared based on continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company began reporting a net loss in fiscal 2020 and reported a net loss of $
8
2. Summary of Significant Accounting Policies
For the Company’s Significant Accounting Policies, please refer to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; liability related to the sale of future royalties; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.
Net Loss per Share
Basic net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. In periods in which the Company has reported a net loss, diluted net loss per common share is the same as basic net loss per common share since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.
|
|
As of June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Options to purchase common stock |
|
|
|
|
|
|
||
Unvested rTSRUs |
|
|
|
|
|
|
||
Unvested PSUs |
|
|
|
|
|
|
||
Unvested restricted stock units |
|
|
|
|
|
|
||
Recently Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. This amendment is effective for the Company in the fiscal year beginning October 1, 2024, and interim periods within the fiscal year beginning October 1, 2025, on a retrospective basis with early adoption permitted. This accounting standard will require additional disclosures about segment information, however, the Company does not expect ASU 2023-07 to have a material impact on the Company’s consolidated financial position or results of operations.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company in the fiscal year beginning October 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2023-09 may have on its financial statement disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”), which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. ASU 2024-03 is effective for the Company in the fiscal year beginning October 1, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 may have on its financial statement disclosures.
9
3. Fair Value of Financial Assets and Liabilities
The following tables present information about the Company’s financial assets and liabilities that were subject to fair value measurement on a recurring basis as of June 30, 2025 and September 30, 2024, and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value:
|
|
Fair Value Measurements as of June 30, 2025 Using: |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. Treasury notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Series 1 nonconvertible preferred stock |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
Fair Value Measurements as of September 30, 2024 Using: |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. Treasury notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Series 1 nonconvertible preferred stock |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
During the three and nine months ended June 30, 2025 and 2024, there were
The fair value of Level 1 instruments are valued using quoted prices in active markets. The fair value of Level 2 instruments classified as marketable securities are typically determined through third-party pricing services. The pricing services use many observable market inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, and current spot rates.
The
The recurring Level 3 fair value measurements of the Company’s outstanding Series 1 nonconvertible preferred stock using probability-weighted discounted cash flow include the following significant unobservable inputs:
|
|
Range |
|
||
|
|
June 30, |
|
September 30, |
|
Unobservable Input |
|
2025 |
|
2024 |
|
Probabilities of payout |
|
|
|
||
Discount rate |
|
|
|
||
There were
10
4. Marketable Securities
As of June 30, 2025 and September 30, 2024, the fair value of available-for-sale marketable securities, by type of security, was as follows:
|
|
June 30, 2025 |
|
|||||||||||||||||
|
|
Amortized |
|
|
Gross |
|
|
Gross |
|
|
Credit Losses |
|
|
Fair Value |
|
|||||
|
|
(in thousands) |
|
|||||||||||||||||
U.S. Treasury notes |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
— |
|
|
$ |
|
|||
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
— |
|
|
$ |
|
|||
|
|
September 30, 2024 |
|
|||||||||||||||||
|
|
Amortized |
|
|
Gross |
|
|
Gross |
|
|
Credit Losses |
|
|
Fair Value |
|
|||||
|
|
(in thousands) |
|
|||||||||||||||||
U.S. Treasury notes |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
||||
As of June 30, 2025 and September 30, 2024, marketable securities consisted of investments that mature within
5. Property and Equipment, Net
Property and equipment, net consisted of the following as of June 30, 2025 and September 30, 2024:
|
|
June 30, |
|
|
September 30, |
|
||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Leasehold improvements |
|
$ |
|
|
$ |
|
||
Laboratory and office equipment |
|
|
|
|
|
|
||
Furniture |
|
|
|
|
|
|
||
Computer equipment |
|
|
|
|
|
|
||
Purchased software |
|
|
|
|
|
|
||
Construction in progress |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Less: Accumulated depreciation and amortization |
|
|
( |
) |
|
|
( |
) |
|
|
$ |
|
|
$ |
|
||
As of September 30, 2024, construction in progress related primarily to leasehold improvements for the new laboratory and office space located at 4 Kingsbury Avenue in Watertown, Massachusetts. We moved into the facility in November 2024 and placed substantially all of those costs into service at that time.
11
6. Accrued Expenses
Accrued expenses and other current liabilities consisted of the following as of June 30, 2025 and September 30, 2024:
|
|
June 30, |
|
|
September 30, |
|
||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Accrued payroll and related expenses |
|
$ |
|
|
$ |
|
||
Accrued research and development expenses |
|
|
|
|
|
|
||
Accrued professional fees |
|
|
|
|
|
|
||
Accrued pharmaceutical drug manufacturing |
|
|
|
|
|
|
||
Accrued other |
|
|
|
|
|
|
||
|
|
$ |
|
|
$ |
|
||
7. AbbVie Collaboration
The Company has a Collaborative Development and License Agreement (as amended, the “AbbVie Agreement”), with AbbVie to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir, under which the Company has received license payments, proceeds from a sale of preferred stock, research funding payments, milestone payments and royalties totaling approximately $
The Company is receiving annually tiered royalties per Company protease product ranging
8. Liability Related to the Sale of Future Royalties
In April 2023, the Company entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which the Company was paid a $
Because the royalty sale agreement will be paid back to OMERS up to a capped amount as well as the Company’s significant continuing involvement in the generation of future cash flows under its AbbVie Agreement, the Company recorded the proceeds from the transaction as a liability on its condensed consolidated balance sheets which will be amortized as interest expense in the condensed consolidated statements of operations under the effective interest rate method over the life of the royalty sale agreement. The Company will continue to record the full amount of royalties earned on MAVYRET/MAVIRET sales as royalty revenue in the condensed consolidated statements of operations.
The Company’s liability related to the sale of future royalties is estimated based on forecasted worldwide MAVYRET/MAVYRET royalties to be paid to OMERS over the course of the royalty sale agreement. This estimate requires significant judgment, including the amount and timing of royalty payments up until the end of the royalty sale agreement, which is estimated to be the stated term of June 30, 2032. As royalties are earned by OMERS, the liability is reduced on the Company’s condensed consolidated balance sheets.
At June 30, 2025, the estimated future cash flows resulted in an effective annual imputed interest rate of approximately
The following table summarizes the activity of the liability related to the sale of future royalties:
|
|
Liability related to the sale of future royalties |
|
|
|
|
(in thousands) |
|
|
Balance - September 30, 2024 |
|
$ |
|
|
Royalty payable to purchaser |
|
|
( |
) |
Payments on royalty sale liability |
|
|
( |
) |
Interest expense, net of capitalized interest of $ |
|
|
|
|
Balance - June 30, 2025 |
|
$ |
|
|
12
9. Stock-Based Awards
The Company grants stock-based awards, including stock options, restricted stock units and other unit awards under its 2019 Equity Incentive Plan (the “2019 Plan”), which was approved by its stockholders on February 28, 2019 and amended in March 2021, March 2022, March 2023, March 2024, December 2024, and March 2025, and its 2024 Inducement Stock Incentive Plan, which was adopted by the Board of Directors in April 2024 and amended in December 2024 for awards to new employees. The Company also has outstanding stock option awards under its 2012 Equity Incentive Plan (the “2012 Plan”), but is no longer granting awards under this plan.
The following table summarizes stock option activity, including performance-based options, for the year-to-date period ending June 30, 2025:
|
|
Shares |
|
|
Weighted |
|
|
Weighted |
|
|
Aggregate |
|
||||
|
|
(in thousands) |
|
|
|
|
|
(in years) |
|
|
(in thousands) |
|
||||
Outstanding as of September 30, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Granted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Exercised |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Forfeited |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Expired |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Outstanding as of June 30, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Options vested and expected to vest as of |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Options exercisable as of June 30, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Market and Performance-Based Stock Unit Awards
The Company awards both performance share units, or PSUs, and relative total stockholder return units, or rTSRUs, to its executive officers. The number of units granted represents the target number of shares of common stock that may be earned; however, the actual number of shares that may be earned ranges from
|
|
PSUs |
|
|
rTSRUs |
|
||||||||||
|
|
Shares |
|
|
Weighted |
|
|
Shares |
|
|
Weighted |
|
||||
|
|
(in thousands) |
|
|
|
|
|
(in thousands) |
|
|
|
|
||||
Unvested as of September 30, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Granted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Vested |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Cancelled |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Unvested as of June 30, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Restricted Stock Units
The following table summarizes the restricted stock unit activity for the year-to-date period ending June 30, 2025:
|
|
Restricted Stock |
|
|
Weighted |
|
||
|
|
(in thousands) |
|
|
|
|
||
Unvested as of September 30, 2024 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
|
|
||
Vested |
|
|
( |
) |
|
|
|
|
Cancelled |
|
|
( |
) |
|
|
|
|
Unvested as of June 30, 2025 |
|
|
|
|
$ |
|
||
13
Stock-Based Compensation Expense
During the three and nine months ended June 30, 2025 and 2024, the Company recognized the following stock-based compensation expense:
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Research and development |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Stock options |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Restricted stock units |
|
|
|
|
|
|
|
|
|
|
|
|
||||
rTSRUs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Performance stock units |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
During the three and nine months ended June 30, 2025 and 2024, the Company recognized stock-based compensation expense for performance-based stock units for which vesting became probable upon achievement of performance-based targets that occurred during the performance period.
As of June 30, 2025, the Company had an aggregate of $
10. Income Taxes
For the three months ended June 30, 2025 and 2024, the Company recorded an income tax expense of $
On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act ("OBBBA"), which includes several changes to U.S. federal income tax law, including the temporary and permanent extension of expiring provisions of the Tax Cuts and Jobs Act of 2017. The Company is assessing these impacts on its consolidated financial statements.
11. Commitments and Contingencies
Litigation and Contingencies Related to Use of Intellectual Property
From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. Except as described below, the Company currently is not a party to any material threatened or pending litigation. However, third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Such third parties may resort to litigation against the Company or its collaborators, which the Company has agreed to indemnify. With respect to some of these patents, the Company expects that it will be required to obtain licenses and could be required to pay license fees or royalties, or both. These licenses may not be available on acceptable terms, or at all. A costly license, or inability to obtain a necessary license, would have a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
In June 2022, the Company announced that it filed suit in the United States District Court for the District of Massachusetts on June 21, 2022, against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the ’953 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). The United States Patent and Trademark Office awarded the ’953 Patent to the Company in June 2022 based on the Company's July 2020 patent application describing coronavirus protease inhibitors invented by the Company. The Company is seeking fair compensation for Pfizer’s use of a coronavirus protease inhibitor claimed in the ’953 patent. In May 2024, the Company and Pfizer each filed motions for summary judgment and a hearing on the motions was held on July 31, 2024. On December 23, 2024, the District Court issued a summary judgment decision ruling that the asserted claims of the ’953 Patent were invalid. In its decision, the District Court also denied the Company’s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. On February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit. The Company filed its
14
opening brief with the Federal Circuit on March 21, 2025. On May 21, 2025, Pfizer filed its response brief. The Company filed its reply on June 13, 2025. The timing for a decision on the appeal is currently uncertain. The Company records all legal expenses associated with the patent infringement suit as incurred in the consolidated statements of operations.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to customers, vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from services to be provided to the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. In addition, the Company maintains directors’ and officers’ insurance coverage. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2025.
Leases
The Company has two real estate leases for properties located in Watertown, Massachusetts. The first lease is for office space located at 400 Talcott Avenue and the second lease is for office and laboratory space located at 4 Kingsbury Avenue.
Future annual minimum facility and equipment lease payments, net of the tenant improvement allowance under the Company’s 4 Kingsbury Avenue lease, as of June 30, 2025, are as follows:
Years ended September 30, |
|
(in thousands) |
|
|
Remaining fiscal 2025 |
|
$ |
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
Thereafter |
|
|
|
|
Total future minimum lease payments |
|
|
|
|
Less: imputed interest |
|
|
( |
) |
Less: tenant improvement allowance |
|
|
( |
) |
Total operating lease liabilities |
|
$ |
|
|
15
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q, or Form 10-Q, and the audited consolidated financial statements and notes thereto for our fiscal year ended September 30, 2024 included in our Annual Report on Form 10-K for that fiscal year, which is referred to as our 2024 Form 10-K. Please refer to our note regarding forward-looking statements on page 2 of this Form 10-Q, which is incorporated herein by this reference.
The Enanta name and logo are our trademarks. This Form 10-Q also includes trademarks, trade names and service marks of other persons. All other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners.
Overview
We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.
Virology:
We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading brand of direct-acting antiviral, or DAA, combination treatment for HCV, which has been marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017.
Our active development programs in virology are focused on respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia and leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults. Estimates suggest that, on average, each year RSV leads to three million hospitalizations globally in children under 5 years old and 177,000 hospitalizations in the U.S. in adults over the age of 65. Populations at high risk for severe RSV infection include infants and young children, adults older than 65 years of age, and those with comorbidities such as chronic heart or lung disease.
We also have development stage programs in virology for the following disease targets:
Immunology:
In immunology, we are designing and developing highly potent and selective oral small molecule inhibitors for the treatment of inflammatory disease by targeting key mechanisms of immune response. Our initial focus has been on mechanisms involved in an overactive type 2 immune phenotype, which is part of the immune response upon encountering infections or allergens. An overactive response is a primary driver of a number of inflammatory diseases.
Our initial immunology targets involve the following mechanisms:
These mechanisms are implicated, along with others, in several diseases, and it is not uncommon for an efficacious treatment for one disease to be tested and approved for other immunology indications. We currently plan to focus our initial immunology drug development proof-of-concept efforts on the following disease indications:
16
As of June 30, 2025, we had $204.1 million in cash, cash equivalents and short-term marketable securities. Based on our operating plan, we expect that our existing cash, cash equivalents, short-term marketable securities, as well as the cash flows from our retained portion of future HCV royalties, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2028.
Our Wholly-Owned Programs
Our primary wholly-owned research and development programs are in virology and immunology.
RSV. In virology, we have two clinical stage candidates for RSV – zelicapavir (formerly EDP-938) and EDP-323. Both of these compounds are replication inhibitors that work by shutting down replication and the production of new virions, as opposed to the other mechanism in development of fusion inhibition that only blocks viral entry. Zelicapavir, which has Fast Track designation from the U.S. Food and Drug Administration, or FDA, is a potent inhibitor of the RSV N-protein for both major subgroups of RSV, referred to as RSV-A and RSV-B. Zelicapavir has been studied in two Phase 2 studies, each in a different high-risk patient population. EDP-323, which also has a Fast Track designation from the FDA, is an inhibitor of the RSV L-protein for both major subgroups of RSV that has completed a Phase 2 challenge study. We will evaluate potential partnership opportunities to advance our RSV programs to the next stage of clinical development.
17
COVID-19. We leveraged our expertise in developing protease inhibitors to discover compounds specifically designed to target the SARS-CoV-2 virus and potentially other coronaviruses. We selected EDP-235, an oral inhibitor of the coronavirus 3CL protease, also referred to as 3CLpro or the main coronavirus protease, or Mpro, for clinical development. In addition to nanomolar activity against all SARS-CoV-2 variants tested to date, EDP-235 has potent antiviral activity against other human coronaviruses, enabling the potential for a pan-coronavirus treatment, including possibly coronaviruses that may infect human populations in the future. Furthermore, EDP-235 has good tissue distribution, and is projected to have four times higher drug levels in lung tissue compared to plasma.
We will continue to focus on potential collaborations to progress EDP-235, as we will not advance this candidate into Phase 3 studies on our own.
Immunology. We are designing and developing highly potent and selective oral small molecule inhibitors targeting the following mechanisms of immune response:
18
We have utilized our internal chemistry and drug discovery capabilities to generate all of our development-stage programs. We continue to invest substantial resources in research programs to discover compounds targeting new disease areas.
The following table summarizes our product development pipeline in our virology and immunology programs:
*Fixed-dose antiviral combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.).
**Continued development dependent on a future collaboration
***Initial indications. Potential future indications include asthma, chronic inducible urticaria (CIndU), eosinophilic esophagitis (EoE), prurigo nodularis (PN) and others.
Our Royalty Revenue Collaboration and Royalty Sale Agreement
Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie, under which we have discovered and out-licensed to AbbVie two protease inhibitor compounds that have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for HCV.
Glecaprevir is the HCV protease inhibitor we discovered that was developed by AbbVie in a fixed-dose combination with its NS5A inhibitor, pibrentasvir, for the treatment of acute or chronic HCV. This patented combination, currently marketed under the brand names MAVYRET® (U.S.) and MAVIRET® (ex-U.S.), is referred to in this report as MAVYRET/MAVIRET. The first protease inhibitor developed through this collaboration, paritaprevir, is part of AbbVie’s initial HCV regimens, which have been almost entirely replaced by MAVYRET/MAVIRET. Since August 2017, substantially all of our royalty revenue has been derived from AbbVie’s net sales of MAVYRET/MAVIRET for the treatment of chronic HCV. Our ongoing royalty revenues from this regimen consist of annually tiered, double-digit, per-product royalties on 50% of the calendar year net sales of the 2-DAA glecaprevir/pibrentasvir combination in MAVYRET/MAVIRET. The annual royalty tiers return to the lowest tier for sales on and after each January 1. In June 2025, the FDA approved a label expansion for MAVYRET as the first and only treatment for acute HCV.
In April 2023, we entered into a royalty sale agreement with an affiliate of OMERS, a Canadian public employee pension fund, pursuant to which we were paid a $200.0 million cash purchase price in exchange for 54.5% of our future quarterly royalty payments on net sales of MAVYRET/MAVIRET, after June 30, 2023, through June 30, 2032, subject to a cap on aggregate payments to OMERS equal to 1.42 times the purchase price.
For accounting purposes, we continue to record 100% of HCV royalties earned under the AbbVie agreement as royalty revenue in our condensed consolidated statements of operations. The $200.0 million received in April 2023 was recognized on our condensed consolidated balance sheets as a liability, which will be reduced by the payments made to OMERS over the term of the Agreement. We recognize imputed interest expense over the life of the royalty sale agreement based on our estimated future MAVYRET/MAVIRET royalties.
19
Financial Operations Overview
We are currently funding all research and development for our wholly-owned programs, which are targeted toward the discovery and development of novel compounds. As of the date of this report, we are conducting a Phase 2b study of zelicapavir in high-risk adults, which completed enrollment in May 2025, and have completed a Phase 2b study of zelicapavir in pediatric patients and a Phase 2a human challenge study of EDP-323. We are also conducting preclinical research and discovery efforts in the field of immunology.
As a result of the timing of our clinical and preclinical development programs, we expect our research and development expenses will fluctuate from period to period. However, in the next 12 months, we anticipate a reduction in our external research and development expenses, primarily driven by the timing of clinical trials in our RSV programs. These milestones, along with strategic adjustments, have positioned us to reduce spending in 2025 while maintaining our commitment to advancing key programs.
To date, we have funded our operations primarily through milestone and royalty payments received under our collaboration agreement with AbbVie, a $200.0 million payment received in April 2023 from our royalty sale agreement, and our existing cash, cash equivalents, and short-term marketable securities. Based on our operating plan, we believe that our existing cash, cash equivalents and short-term marketable securities, as well as the cash flows from our retained portion of future HCV royalties, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2028.
Revenue
Our revenue is primarily derived from our collaboration agreement with AbbVie and AbbVie’s sales of MAVYRET/MAVIRET, an 8-week treatment regimen for HCV.
The following table is a summary of revenue recognized for the three and nine months ended June 30, 2025 and 2024:
|
|
Three Months Ended June 30, |
|
|
Nine Months Ended June 30, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
(in thousands) |
|
|||||||||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Royalty revenue |
|
$ |
18,314 |
|
|
$ |
17,971 |
|
|
$ |
50,199 |
|
|
$ |
53,028 |
|
Total revenue |
|
$ |
18,314 |
|
|
$ |
17,971 |
|
|
$ |
50,199 |
|
|
$ |
53,028 |
|
AbbVie Agreement
To date, we have received annually tiered, double-digit royalties on our protease inhibitor product glecaprevir included in AbbVie’s net sales of MAVYRET/MAVIRET. Under the terms of our AbbVie Agreement, 50% of AbbVie’s net sales of MAVYRET/MAVIRET are allocated to glecaprevir. Beginning with each January 1, the cumulative net sales of MAVYRET/MAVIRET start at zero for purposes of calculating the tiered royalties. As disclosed above regarding the OMERS royalty sale agreement, we only retain 45.5% of the cash payments from royalties on net sales of MAVYRET/MAVIRET occurring after June 30, 2023 through June 30, 2032, subject to a cap on aggregate payments to OMERS equal to 1.42 times OMERS’ purchase price.
Internal Programs
As our internal product candidates are currently in clinical or preclinical development, we have not generated any revenue from our own product sales. We do not expect to generate any revenue from product sales derived from these product candidates for at least the next several years.
20
Operating Expenses
Our operating expenses are comprised of research and development expenses and general and administrative expenses.
Research and Development Expenses
Research and development expenses consist of costs incurred to conduct basic research, such as the discovery and development of novel small molecules as therapeutics, as well as any external expenses of preclinical and clinical development activities. We expense all costs of research and development as incurred. These expenses consist primarily of:
At any given time, we have later stage programs in clinical development as well as several active early-stage research and drug discovery projects. Our internal resources, employees and infrastructure are utilized across multiple projects, including our early-stage discovery projects. As such, we report information regarding costs incurred based on our programs (i.e., disease area) rather than on a project specific basis. All indirect costs are allocated to programs based on headcount and square footage of our facilities. We expect that our research and development expenses will fluctuate from period to period as we advance our research and development programs. However, in the next 12 months, we anticipate a reduction in our external research and development expenses, primarily driven by the timing of clinical trials in our RSV programs. These milestones, along with strategic adjustments, have positioned us to reduce spending in 2025 while maintaining our commitment to advancing key programs. To date, we have not identified any significant impact of inflation on spending in research and development, but it is uncertain whether there will be inflationary impacts, including as a result of tariffs, in future periods.
Our research and drug discovery and development programs are in early stages; therefore, the successful development of our product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. Given the uncertainty associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of the current or future clinical trials of our product candidates or if, or to what extent, we will generate revenue from the commercialization and sale of any of our product candidates. We anticipate that we will make determinations as to which development programs to pursue and how much funding to direct to each program on an ongoing basis in response to the preclinical and clinical success and prospects of each product candidate, as well as ongoing assessments of the commercial potential of each product candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel costs, which include salaries, related benefits and stock-based compensation, of our executive, finance, business and corporate development and other administrative functions. General and administrative expenses also include travel expenses, allocated facility-related costs not otherwise included in research and development expenses, directors’ and officers’ liability insurance premiums, professional fees for auditing, tax, and legal services, patent expenses and litigation expenses associated with prosecuting our patent infringement suit.
We expect that general and administrative expenses may increase in the long term. To date we have not experienced a significant impact of inflation on general and administrative expenses, but we anticipate inflation may impact future periods.
Other Income (Expense)
Other income (expense) consists of interest expense, interest and investment income, net and the change in fair value of our outstanding Series 1 nonconvertible preferred stock. Interest expense consists of the interest expense and amortization of debt issuance costs associated with the royalty sale agreement with an affiliate of OMERS. Interest income consists of interest earned on our cash equivalents and marketable securities balances. Investment income consists of the amortization or accretion of any purchased premium or discount, respectively, on our marketable securities. The change in fair value of our Series 1 nonconvertible preferred stock relates to the remeasurement of these financial instruments from period to period as these instruments may require a transfer of assets because of the liquidation preference features of the underlying instrument.
Income Tax (Expense) Benefit
Income tax (expense) benefit is based on our best estimate of taxable net income (loss), applicable income tax rates, net research and development tax credits and carryforwards, net operating loss carrybacks and interest earned on such refunds, changes in valuation allowance estimates and deferred income taxes.
21
Results of Operations
Comparison of the Three Months Ended June 30, 2025 and 2024
|
|
Three Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Revenue |
|
$ |
18,314 |
|
|
$ |
17,971 |
|
Research and development |
|
|
27,210 |
|
|
|
28,742 |
|
General and administrative |
|
|
9,997 |
|
|
|
13,414 |
|
Interest expense |
|
|
(1,618 |
) |
|
|
(2,355 |
) |
Interest and investment income, net |
|
|
2,285 |
|
|
|
3,487 |
|
Income tax (expense) benefit |
|
|
(29 |
) |
|
|
395 |
|
Net loss |
|
$ |
(18,255 |
) |
|
$ |
(22,658 |
) |
Revenue
We recognized revenue of $18.3 million during the three months ended June 30, 2025 as compared to $18.0 million during the three months ended June 30, 2024. The $0.3 million increase in revenue was primarily due to AbbVie’s higher reported HCV sales as compared to the same period in 2024.
Our royalty revenues eligible to be earned in the future will depend on AbbVie’s HCV market share, the pricing of the MAVYRET/MAVIRET regimen, the number of patients treated and the effect of the label expansion for MAVYRET in the United States for the treatment of patients with acute HCV. In addition, at the beginning of each calendar year (the second quarter of our fiscal year), our royalty rate resets to the lowest tier for each of our royalty-bearing products licensed to AbbVie.
Beginning with the quarter ended September 30, 2023, 54.5% of our quarterly royalty payments on net sales of MAVYRET/MAVIRET that are included in our total revenue are paid to OMERS through June 30, 2032, subject to a cap on aggregate payments equal to 1.42 times the purchase price. The $200.0 million received in April 2023 was recognized on our condensed consolidated balance sheets as a liability which will be reduced by the payments made to OMERS over the term of the royalty sale agreement. We will continue to record 100% of HCV royalties earned under the AbbVie Agreement as royalty revenue in our condensed consolidated statements of operations since the AbbVie Agreement has not been amended and is independent of our agreement with OMERS.
Research and development expenses
|
|
Three Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
R&D programs: |
|
|
|
|
|
|
||
Virology |
|
|
|
|
|
|
||
RSV |
|
$ |
15,412 |
|
|
$ |
17,935 |
|
COVID-19 |
|
|
88 |
|
|
|
(112 |
) |
HBV |
|
|
49 |
|
|
|
67 |
|
Total Virology |
|
$ |
15,549 |
|
|
$ |
17,890 |
|
Immunology |
|
|
|
|
|
|
||
KIT |
|
|
4,057 |
|
|
|
5,753 |
|
STAT6 |
|
|
4,678 |
|
|
|
1,886 |
|
Total Immunology |
|
$ |
8,735 |
|
|
$ |
7,639 |
|
Other Programs |
|
|
|
|
|
|
||
Early discovery |
|
|
2,895 |
|
|
|
3,121 |
|
Other programs for out-licensing |
|
|
31 |
|
|
|
92 |
|
Total Other Programs |
|
$ |
2,926 |
|
|
$ |
3,213 |
|
|
|
|
|
|
|
|
||
Total research and development expenses |
|
$ |
27,210 |
|
|
$ |
28,742 |
|
22
Research and development expenses for the three months ended June 30, 2025 decreased by $1.5 million compared to the same period in 2024.
Virology
The costs in our virology programs decreased by $2.3 million primarily due to the timing of clinical trials in our RSV programs.
Immunology
The costs in our immunology programs increased by $1.1 million primarily due to the ongoing preclinical studies and lead optimization activities for our STAT6 program.
Other Programs
Other program costs decreased by $0.3 million primarily due to the completion of the discovery-stage activities related to our STAT6 program.
General and administrative expenses
General and administrative expenses decreased by $3.4 million for the three months ended June 30, 2025 compared to the same period in 2024. The change was primarily due to a decrease in legal expenses related to our patent infringement suit against Pfizer.
Other income (expense)
Changes in components of other income (expense) were as follows:
Interest expense
Interest expense decreased by $0.7 million for the three months ended June 30, 2025, as compared to the same period in 2024 due to the paydown of our obligation associated with our royalty sale agreement entered into during April 2023 with an affiliate of OMERS.
Interest and investment income, net
Interest and investment income, net, decreased by $1.2 million for the three months ended June 30, 2025, as compared to the same period in 2024. The decrease was due to lower cash and investment balances year over year.
Income tax (expense) benefit
The income tax expense during the three months ended June 30, 2025 was primarily due to state income taxes. The income tax benefit during the three months ended June 30, 2024 related to interest recorded on our $33.8 million federal tax refund, which we received in April 2025.
On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act ("OBBBA"), which includes several changes to U.S. federal income tax law, including the temporary and permanent extension of expiring provisions of the Tax Cuts and Jobs Act of 2017. The Company is assessing these impacts on its consolidated financial statements.
Results of Operations
Comparison of the Nine Months Ended June 30, 2025 and 2024
|
|
Nine Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Revenue |
|
$ |
50,199 |
|
|
$ |
53,028 |
|
Research and development |
|
|
82,931 |
|
|
|
100,698 |
|
General and administrative |
|
|
34,231 |
|
|
|
44,167 |
|
Interest expense |
|
|
(5,294 |
) |
|
|
(8,359 |
) |
Interest and investment income, net |
|
|
7,376 |
|
|
|
11,594 |
|
Income tax benefit |
|
|
1,692 |
|
|
|
1,380 |
|
Net loss |
|
$ |
(63,189 |
) |
|
$ |
(87,222 |
) |
Revenue
We recognized revenue of $50.2 million during the nine months ended June 30, 2025 as compared to $53.0 million during the nine months ended June 30, 2024. The $2.8 million decrease in revenue was primarily due to AbbVie’s lower reported HCV sales as compared to the same period in 2024.
23
Research and development expenses
|
|
Nine Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
R&D programs: |
|
|
|
|
|
|
||
Virology |
|
|
|
|
|
|
||
RSV |
|
$ |
51,620 |
|
|
$ |
67,936 |
|
COVID-19 |
|
|
504 |
|
|
|
3,871 |
|
HBV |
|
|
125 |
|
|
|
239 |
|
Total Virology |
|
$ |
52,249 |
|
|
$ |
72,046 |
|
Immunology |
|
|
|
|
|
|
||
KIT |
|
|
11,902 |
|
|
|
13,873 |
|
STAT6 |
|
|
10,670 |
|
|
|
2,462 |
|
Total Immunology |
|
$ |
22,572 |
|
|
$ |
16,335 |
|
Other Programs |
|
|
|
|
|
|
||
Early discovery |
|
|
7,955 |
|
|
|
11,799 |
|
Other programs for out-licensing |
|
|
155 |
|
|
|
518 |
|
Total Other Programs |
|
$ |
8,110 |
|
|
$ |
12,317 |
|
|
|
|
|
|
|
|
||
Total research and development expenses |
|
$ |
82,931 |
|
|
$ |
100,698 |
|
Research and development expenses for the nine months ended June 30, 2025 decreased by $17.8 million compared to the same period in 2024.
Virology
The costs in our virology programs decreased by $19.8 million primarily due to the timing of our clinical trials in our RSV programs and, to a lesser extent, a decrease in costs associated with our COVID-19 program as we stopped further internal development and will only progress the program in the context of one or more collaborations.
Immunology
The costs in our immunology programs increased by $6.2 million primarily due to the initiation of preclinical studies and lead optimization activities for our STAT6 program.
Other Programs
Other program costs decreased by $4.2 million primarily due to the completion of the discovery-stage activities related to our STAT6 program.
General and administrative expenses
General and administrative expenses decreased by $9.9 million for the nine months ended June 30, 2025 compared to the same period in 2024. The change was primarily due to a decrease in legal expenses related to our patent infringement suit against Pfizer.
Other income (expense)
Changes in components of other income (expense) were as follows:
Interest expense
Interest expense decreased by $3.1 million for the nine months ended June 30, 2025, as compared to the same period in 2024 due to the paydown of our obligation associated with our royalty sale agreement entered into during April 2023 with an affiliate of OMERS.
Interest and investment income, net
Interest and investment income, net, decreased by $4.2 million for the nine months ended June 30, 2025, as compared to the same period in 2024. The decrease was due to lower cash and investment balances year over year.
Income tax benefit
The income tax benefit during the nine months ended June 30, 2025 was primarily due to an additional federal tax refund from a net operating loss carryback of $0.9 million. The income tax benefit during the nine months ended June 30, 2024 related to interest recorded on our federal tax refund. We received our federal tax refund of $33.8 million in April 2025.
24
On July 4, 2025, the U.S. government enacted the OBBBA, which includes several changes to U.S. federal income tax law, including the temporary and permanent extension of expiring provisions of the Tax Cuts and Jobs Act of 2017. The Company is assessing the impact of these changes on its consolidated financial statements.
Liquidity and Capital Resources
We fund our operations with cash flows from our retained portion of our royalty revenue and our existing financial resources. At June 30, 2025, our principal sources of liquidity were cash and cash equivalents and short-term marketable securities of $204.1 million.
The following table shows a summary of our cash flows:
|
|
|
|
|||||
|
|
Nine Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Cash provided by (used in): |
|
|
|
|
|
|
||
Operating activities |
|
$ |
(12,783 |
) |
|
$ |
(68,364 |
) |
Investing activities |
|
|
38,051 |
|
|
|
39,162 |
|
Financing activities |
|
|
(18,297 |
) |
|
|
(20,411 |
) |
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
$ |
6,971 |
|
|
$ |
(49,613 |
) |
Net cash used in operating activities
Cash used in operating activities was $12.8 million for the nine months ended June 30, 2025 as compared to cash used in operating activities of $68.4 million for the same period in 2024. Our cash used in operating activities decreased $55.6 million primarily due to lower research and development payments and receipt of a $33.8 million income tax refund in April 2025, offset by lower cash receipts associated with our AbbVie agreement.
Net cash provided by investing activities
Cash provided by investing activities was $38.1 million for the nine months ended June 30, 2025 as compared to cash provided by investing activities of $39.2 million for the same period in 2024. Our cash provided by investing activities decreased $1.1 million, driven by the timing of maturities of marketable securities in 2025 compared to 2024.
Net cash used in financing activities
Cash used in financing activities was $18.3 million for the nine months ended June 30, 2025 as compared to cash used in financing activities of $20.4 million for the same period in 2024. Our cash used in financing activities decreased $2.1 million, driven primarily by lower payments on our royalty sale agreement with OMERS.
Funding Requirements
As of June 30, 2025, we had $204.1 million in cash, cash equivalents and short-term marketable securities. Based on our operating plan, we believe that our existing cash, cash equivalents and short-term marketable securities as of June 30, 2025, as well as our retained portion of future HCV royalties, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2028. However, our projection of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.
Our future capital requirements are difficult to forecast and will depend on many factors, including:
25
Off-Balance Sheet Arrangements
We do not engage in any off-balance sheet financing activities. We do not have any interest in entities referred to as variable interest entities, which include special purpose entities and other structured finance entities.
Contractual Obligations and Commitments
Facility Leases
As of the date of this report, we lease space in Watertown, Massachusetts, under two separate lease agreements with one landlord.
In May 2022, we entered into a ten-year lease for new laboratory and office space in Watertown, Massachusetts, adjacent to our 400 Talcott Avenue premises at Arsenal on the Charles at 4 Kingsbury Avenue since our lease for office and laboratory space at 500 Arsenal Street was to expire on September 1, 2027. The construction of the facility shell was completed and we gained access to the building to construct tenant improvements during the three months ended March 31, 2024. Upon gaining access to the 4 Kingsbury Avenue building, we capitalized a right-of-use asset and lease liability of approximately $32 million on our consolidated balance sheets which reflects our fixed base rent payments, net of approximately $15 million of a tenant improvement allowance provided by the landlord, over the 10-year term of the lease. The 4 Kingsbury Avenue lease ends on September 30, 2034.
In conjunction with the commencement of our lease at 4 Kingsbury Avenue, during the three months ended March 31, 2024, we adjusted our 500 Arsenal Street lease liability to shorten the expiration date from September 2027 to the date the 4 Kingsbury Avenue building became ready for our occupancy. This resulted in a decrease in the lease liability and right-of-use asset on our consolidated balance sheets by approximately $9.0 million. The rent commencement date for our 4 Kingsbury Avenue lease was September 12, 2024, and we moved into the space in November 2024, at which time our lease at 500 Arsenal Street expired.
The second lease for office space located at 400 Talcott Avenue commenced on September 24, 2018 for a term of six years. In May 2022, we amended this lease to expand the rented space and extend the lease term through June 1, 2034. We spent approximately $6.3 million in capital expenditures for the additional space, which primarily relate to tenant improvements. We received a tenant improvement allowance from the landlord of $2.5 million. In July 2024, we amended our lease agreement to confirm alignment with the lease end date of our 4 Kingsbury Avenue lease at September 30, 2034.
Total estimated minimum lease payments for the next 5 years and thereafter under our existing facility and leased equipment agreements are $2.2 million for the remainder of 2025, $8.5 million in 2026, $8.7 million in 2027, $9.0 million in 2028, $9.3 million in 2029, and $50.6 million thereafter.
OMERS Agreement
In April 2023, we entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which we were paid a $200.0 million cash purchase price in exchange for 54.5% of our future quarterly royalty payments on net sales of MAVYRET/MAVIRET after June 30, 2023, through June 30, 2032, subject to a cap on aggregate payments equal to 1.42 times the purchase price.
The $200.0 million received in April 2023 was recognized on our condensed consolidated balance sheets as a liability which will be reduced by the payments made to OMERS over the term of the Agreement.
26
Critical Accounting Policies
Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. See our 2024 Form 10-K for information about our critical accounting policies as well as a description of our other significant accounting policies. There have been no significant changes to our critical accounting policies since the beginning of this fiscal year.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is set forth in Note 2 to the condensed consolidated financial statements included in this Form 10-Q.
27
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
During the nine months ended June 30, 2025, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures and Internal Control over Financial Reporting
Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of the principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this quarterly report. Based on this evaluation, the principal executive officer and principal financial officer concluded that these disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods.
Changes in Internal Control Over Financial Reporting.
There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II —OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Information with respect to legal proceedings is included in Note 11 of the Notes to the Unaudited Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
ITEM 1A. RISK FACTORS
Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the detailed discussion of risk factors included in our 2024 Form 10-K.
There have been no material changes to such risk factors during the quarter ended June 30, 2025. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements. During the three months ended June 30, 2025, the officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company set forth below adopted or terminated a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c).
Except as set forth above, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
28
ITEM 6. EXHIBITS
|
|
|
|
Incorporated by Reference |
|
|
||||||
Exhibit Number |
|
Exhibit Description |
|
Form |
|
Date |
|
Exhibit Number |
|
File Number |
|
Filed Herewith |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1 |
|
Restated Certificate of Incorporation of Enanta Pharmaceuticals, Inc. |
|
8-K |
|
03/28/2013 |
|
3.1 |
|
001-35839 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2 |
|
Amended and Restated Bylaws of Enanta Pharmaceuticals, Inc. (as amended and restated in August 2015) |
|
8-K |
|
08/18/2015 |
|
3.2 |
|
001-35839 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1 |
|
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. |
|
— |
|
— |
|
— |
|
— |
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. |
|
— |
|
— |
|
— |
|
— |
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1 |
|
Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
— |
|
— |
|
— |
|
— |
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS |
|
XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema with embedded Linkbases document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (formatted as Inline XBRL with applicable Taxonomy Extension information contained in Exhibit 101). |
|
|
|
|
|
|
|
|
|
X |
29
ENANTA PHARMACEUTICALS, INC.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
Date: August 13, 2025 |
|
|
|
|
|
|
|
/s/ Paul J. Mellett |
|
|
Paul J. Mellett Chief Financial and Administrative Officer (Principal Financial and Accounting Officer) |
30
FAQ
How much cash does Enanta (ENTA) have and how long is the runway?
What were ENTA's revenue and net loss for the quarter and nine months?
What is the status and size of the royalty sale liability on Enanta's balance sheet?
What clinical progress has ENTA reported for its RSV programs?
What is the status of Enanta’s patent litigation with Pfizer?
